Moderna has released the final results of a 30,000-person trial of its COVID-19 vaccine candidate, reinforcing the strong results seen with interim data that showed 94.1% efficacy. A total of 11 people in the group receiving two doses of the vaccine developed symptoms after testing positive for COVID-19, compared to 185 in the group receiving placebo. In addition, the vaccine showed 100% efficacy against severe disease as no individuals who received it ended up developing severe COVID-19, compared to 30 in the placebo group, an important consideration in assessing the level of protection provided.